The Cross-Border Biotech Blog

Equity Research Resumes at Bloom Burton

It’s good to be back! – covering interesting companies in a sector that’s showing real signs of improved fundamentals since my last equity research report, which was published 4 years ago. Glad also that I’ve landed at Bloom Burton, re-joining a group that was active, and in many cases, pivotal, to introducing investors to a […]

read more


CB_BTB_Title

“Canada is a world leader in science, technology and innovation, and is recognized as one of the most innovative and competitive economies in the world.” A quotation from the Government of Canada web site which I believe is fairly close to reality. The Council of Canadian Academies prepared a report entitled “Paradox Lost: Explaining Canada’s Research […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for December 8th, 2014!   The past weeks saw a variety activity, including Knight Therapeutics’ bought deal for an offering of up to about $100 million, their secured loan to CRH Medical Corporation for CRH’s acquisition of Gastroenterology Anesthesia Associates, LLC, and Valeant’s redemption of $445 in senior […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for November 17th, 2014!   This week started off with a bang, as Allergan have announced their acceptance of a $66 billion takeover bid from Actavis Plc, closing the door on a hostile offer from activist investor William Ackman and Valeant Pharmaceuticals International Inc. The deal values Allergan […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for November 10th, 2014!   This week, Profound Medical has announced their intention to go public.  In addition, Profound intends to complete a brokered private placement for gross proceeds of up to $30 million. For more details on this story as well as many more, keep reading! Mira […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for October 27th, 2014!   Zymeworks, which combines proprietary molecular simulation technology with high performance computing to design and optimize protein therapeutics, had some significant announcements this week, closing a $17.3 million offering while also obtaining a $375 million licensing, collaboration and equity investment arrangement with Eli Lilly.  […]

read more


Q3Banner

    In this blog, I am going to comment on the Q3 performance of the group of 60 companies which had share prices of between $0.10 and $0.99 to start 2014. Q3 Results Decliners barely outnumbered advancers by 30 to 29 (Welichem Biotech not included in this analysis) Average and median share price changes […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for October 20th, 2014!   Welcome to your deal review for October 20th, 2014! After a hiatus last week due to Canadian Thanksgiving and our friends to the south celebrating Columbus Day, this week’s post covers deal activity from October 6th 2014. The past two weeks saw notable […]

read more


Q3Banner

    Quiet, no momentum, but Therapeutics – Commercial companies still moved ahead There was renewed interest in the Canadian healthcare sector in the first half of 2014. The institutional interest was focused on the Therapeutics – Commercial group where there were revenues, profitability and tax-inversion potential. In Q1, there was also broader sector momentum […]

read more